Viking Therapeutics Inc (VKTX)
72.88
+0.34
(+0.47%)
USD |
NASDAQ |
Nov 01, 16:00
73.42
+0.54
(+0.74%)
After-Hours: 20:00
Viking Therapeutics Enterprise Value: 7.191B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 7.191B |
| October 31, 2024 | 7.153B |
| October 30, 2024 | 7.065B |
| October 29, 2024 | 7.243B |
| October 28, 2024 | 7.374B |
| October 25, 2024 | 7.765B |
| October 24, 2024 | 7.229B |
| October 23, 2024 | 5.799B |
| October 22, 2024 | 5.982B |
| October 21, 2024 | 6.239B |
| October 18, 2024 | 6.402B |
| October 17, 2024 | 6.270B |
| October 16, 2024 | 6.408B |
| October 15, 2024 | 6.355B |
| October 14, 2024 | 6.402B |
| October 11, 2024 | 6.406B |
| October 10, 2024 | 6.029B |
| October 09, 2024 | 6.050B |
| October 08, 2024 | 6.500B |
| October 07, 2024 | 6.091B |
| October 04, 2024 | 6.308B |
| October 03, 2024 | 6.214B |
| October 02, 2024 | 6.278B |
| October 01, 2024 | 5.979B |
| September 30, 2024 | 6.124B |
| Date | Value |
|---|---|
| September 27, 2024 | 5.886B |
| September 26, 2024 | 5.963B |
| September 25, 2024 | 6.052B |
| September 24, 2024 | 5.919B |
| September 23, 2024 | 6.261B |
| September 20, 2024 | 6.866B |
| September 19, 2024 | 6.610B |
| September 18, 2024 | 6.199B |
| September 17, 2024 | 6.031B |
| September 16, 2024 | 6.492B |
| September 13, 2024 | 6.451B |
| September 12, 2024 | 6.017B |
| September 11, 2024 | 5.797B |
| September 10, 2024 | 5.113B |
| September 09, 2024 | 5.127B |
| September 06, 2024 | 5.055B |
| September 05, 2024 | 5.195B |
| September 04, 2024 | 5.495B |
| September 03, 2024 | 5.527B |
| August 30, 2024 | 6.162B |
| August 29, 2024 | 5.999B |
| August 28, 2024 | 5.834B |
| August 27, 2024 | 5.862B |
| August 26, 2024 | 6.317B |
| August 23, 2024 | 6.218B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-25.30M
Minimum
Mar 16 2020
9.627B
Maximum
Mar 04 2024
1.273B
Average
254.17M
Median
Jul 06 2021
Enterprise Value Benchmarks
| Amgen Inc | 222.98B |
| Eli Lilly and Co | 805.11B |
| Pfizer Inc | 221.03B |
| Structure Therapeutics Inc | 1.426B |
| Altimmune Inc | 314.11M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -24.94M |
| Total Expenses (Quarterly) | 36.56M |
| EPS Diluted (Quarterly) | -0.22 |
| Earnings Yield | -1.28% |